Viking Therapeutics Poised for Growth Amid GLP-1 Market Surge
PILLAR DIAGNOSTIC // WEEK 04
“Viking’s strong trial execution and healthy cash cushion set the stage for further share gains and potential M&A interest before the market fully prices in intensifying GLP-1 competition, with upside likely grinding higher into differentiation data.”
Proposed action
Overweight
THE MECHANICS
Tape & flow
—
THE MACHINE
Operational momentum
VK2735 has completed enrollment in the 78-week Phase 3 obesity trial and is on track to finish diabetes trial enrollment by early 2026, reflecting strong development execution and a robust pipeline backed by healthy cash reserves that position Viking as an attractive acquisition candidate.
THE MAP
Structure & constraints
Competition intensifies in the GLP-1 obesity therapy market as Viking Therapeutics advances its dual GIP/GLP-1 receptor agonist in both oral and subcutaneous formulations.
THE MOOD
Consensus & positioning
Despite looming negative EPS revisions and a Zacks Sell rating, sentiment remains bullish on Viking’s GLP-1 pipeline, with analysts projecting 150%+ upside, takeover speculation, and expectations of shares doubling on solid clinical progress.